T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy
Summary:
The NCI seeks applications from parties interested in co-developing and/or licensing a method to develop improved cancer immunotherapies.
The NCI seeks applications from parties interested in co-developing and/or licensing a method to develop improved cancer immunotherapies.
The NCI is seeking research co-development and/or licensees for the HLA-A*01:01 restricted human T-cell receptor recognizing the NRAS Q61K hotspot mutation.
The tumor microenvironment (TME) is a complex mixture of cell types whose interactions affect tumor growth and clinical outcome. Recent studies using fluorescence-activated cell sorting (FACS) and single-cell RNA sequencing (RNAseq) to elucidate tissue composition and cell-cell interactions in the TME led to improved biomarkers of patient response and new treatment opportunities.
NCI is seeking parties to non-exclusively license the A2243 human synovial sarcoma cell line.
The National Institutes of Health is seeking commercial partners to co-develop and/or license a heterocyclic scaffold for development of therapeutics against Plk1-dependent cancers.
The Retroviral Replication Laboratory of the National Cancer Institute actively seeks parties interested in non-exclusive licensing a collection of single-round vectors containing mutations in HIV-1 IN or RT.
NCI seeks proposals from parties interested in licensing an improved method for the identification of TCRs from bulk populations of TIL for the development of cancer immunotherapies.
This technology describes additional methods of using the griffithsin anti-viral polypeptides described in related NCI invention (reference number E-106-2003). Specifically, this invention describes the use of GRFT to inhibit viral infection of hepatitis C viral infection, a severe acute respiratory syndrome (SARS) viral infection, an H5N1 viral infection, or an Ebola viral infection.
The NIA seeks co-development partners and/or licensees for the further development of Cα-peptide as a therapeutic that inhibits islet amyloidosis.
NICHD is seeking research co-development partners and/or licensees for development of this invention as a male contraceptive.